R1 RCM Inc
NASDAQ:RCM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.11
14.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
R1 RCM Inc
R1 RCM Inc
Cash & Cash Equivalents
R1 RCM Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
R1 RCM Inc
NASDAQ:RCM
|
Cash & Cash Equivalents
$167.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-1%
|
|
|
DaVita Inc
NYSE:DVA
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash & Cash Equivalents
$764m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash & Cash Equivalents
$6.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
20%
|
|
|
Cigna Corp
NYSE:CI
|
Cash & Cash Equivalents
$5.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash & Cash Equivalents
$1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
33%
|
CAGR 10-Years
10%
|
|
R1 RCM Inc
Glance View
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. The company is headquartered in Chicago, Illinois and currently employs 10,200 full-time employees. The company went IPO on 2010-05-20. The firm's services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also improving patient, physician, and staff satisfaction for its customers. Its primary service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups. The company also offers modular services, allowing customers to engage for only specific components of its end-to-end RCM service offering, such as physician advisory services (PAS), practice management (PM), revenue integrity solutions (RIS), patient experience (PX), coding management, and business office services. Its PAS offering assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes.
See Also
What is R1 RCM Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
167.3m
USD
Based on the financial report for Sep 30, 2024, R1 RCM Inc's Cash & Cash Equivalents amounts to 167.3m USD.
What is R1 RCM Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-1%
Over the last year, the Cash & Cash Equivalents growth was 1%. The average annual Cash & Cash Equivalents growth rates for R1 RCM Inc have been 2% over the past three years , 25% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
